Although the science underlying the way in which medicines are developed has evolved, there has been little change in how we pay for them. Increasingly, medicines will have multiple indications. New payment mechanisms are being proposed to better align reimbursement policies with the innovation landscape. One such mechanism is allowing the healthcare system to support different prices for different indications of a medicine: indication-based pricing (IBP).
OHE has today launched a Discussion Paper, which outlines the key potential benefits and drawbacks of IBP, along with considerations for implementation. This is accompanied by a consultation exercise, where we ask you to contribute your thoughts.
The consultation closes in six weeks, on Monday 24th June 2019.
Cole, A., Towse, A. and Zamora, B., 2019. Indication-Based Pricing (IBP) Discussion Paper. OHE Briefing, London: Office of Health Economics.
Mestre-Ferrandiz, J., Towse, A., Dellamano, R. and Pistollato, M., 2015. Multi-indication pricing: pros, cons and applicability to the UK. OHE Seminar Briefing, Office of Health Economics.
Cole, A., Towse, A., Lorgelly, P. and Sullivan, R., 2018. Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals. Research Paper, Office of Health Economics.
Towse, A., Cole, A. and Zamora, B., 2018. The Debate on Indication-Based Pricing in the US and Five Major European Countries. Consulting Report, Office of Health Economics.
Neri, M., Towse, A., and Garau, M., 2018. Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward. OHE Briefing, Office of Health Economics.
Posted in OHE Consulting | Tagged Briefing